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Background: This study evaluated the incidence, complications, and outcome of local intra-arterial thrombolytic therapy
for acute superior mesenteric artery (SMA) occlusion in Sweden.
Methods: Patients undergoing local intra-arterial thrombolytic therapy for acute SMA occlusion were identified in the
Swedish Vascular Registry (SWEDVASC) between 1987 and 2009. Patient data were retrieved in a structured protocol
by local vascular surgeons at each participating hospital.
Results: Included were 34 patients (20 women) from 12 hospitals. Median age was 78 years. The first patient was treated
in 1997, and the annual number of patients undergoing thrombolysis increased continuously from 2004 to 2009.
Twenty-eight patients (82%) had embolic occlusion. No patients (0%) had acute peritonitis, and one (3%) had bloody
stools at admission. Thirty-two patients (94%) were diagnosed by computed tomography with intravenous contrast
enhancement. The median dose of alteplase was 20 mg (interquartile range, 11.6-34.0). Successful thrombolysis was
achieved in 30 patients (88%). Initial adjunctive aspiration thromboembolectomy was performed in 10 patients. There
were six self-limiting bleeding complications; one from the gastrointestinal tract. Thirteen explorative laparotomies, 10
repeat laparotomies, and eight bowel resections were performed. The in-hospital mortality rate was 26% (9 of 34). Age
was not associated with in-hospital death (P  .42). Successful thrombolysis was associated with decreased mortality
(P  .048).
Conclusion: Local thrombolysis for acute SMA occlusion is a minimally invasive and effective treatment alternative in a





























JThe prognosis for patients with acute intestinal isch-
emia due to acute superior mesenteric artery (SMA) occlu-
sion is still poor.1 The main reason for this has been
diagnostic difficulties and delayed laparotomy. In a small
proportion of patients, surgery with a limited bowel resec-
tion might be successful; however, revascularization of the
SMA is a prerequisite for survival in most patients. During
the last decade, a few centers have reported improved
outcome as a result of the use of fast and available high-
resolution computed tomography (CT) scanners2 as well as
the development of open and endovascular techniques for
acute SMA occlusion.3,4
The number of intestinal revascularizations in patients
with acute intestinal ischemia has increased significantly
over time in Sweden.5,6 Local intra-arterial thrombolysis is
a minimally invasive treatment option for these often el-
derly patients with multiple comorbidities. Successful local
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1734ntra-arterial thrombolysis for acute SMA occlusion was
rst performed in 1997 in Sweden,7 but there are concerns
ith this method. Thrombolysis may not be appropriate for
atients with an advanced stage of intestinal ischemia and
eritonitis, where it is believed that the clot should be
emoved in a more urgent manner before laparotomy and
ssessment of bowel viability. Moreover, the gastrointesti-
al mucosa responds with a hemorrhagic transformation
econdary to ischemia, and theoretically, may be a source of
ajor bleeding during thrombolysis. Clinicians may there-
ore be reluctant to propose this, in their mind, hazardous
reatment alternative. The aim of this study was to evaluate
he incidence, complications, and outcome after local intra-
rterial thrombolytic therapy for acute SMA occlusion.
ATIENTS AND METHODS
This study was approved by the Regional Research
thics Committee of the Uppsala/Örebro region. Patients
ndergoing continuous local intra-arterial thrombolytic
herapy for acute SMA occlusion were identified in the
wedish Vascular (SWEDVASC) registry between 1987
nd December 31, 2009. Previous reports had identified
wo patients between 1987 and 19985 and 13 patients
etween 1999 and 2006,6 respectively. The proportion
f patients receiving local thrombolysis among patients
ndergoing intestinal revascularization between 1987
nd 2006 was 6.7% (15 of 223). A renewed search in
WEDVASC found that 19 patients underwent thromboly-
is for acute SMA occlusion or the celiac trunk between
anuary 1, 2007, and December 31, 2009. From the total
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Volume 54, Number 6 Björnsson et al 1735received one injection of thrombolytic agent during open
embolectomy and one patient with endovascular aspiration
embolectomy, thus 34 patients from 12 hospitals were
included.
Retrieval of data. Patients were registered prospec-
tively in the SWEDVASC registry, and data were supple-
mented with a structured protocol that was sent to local
vascular surgeons at each participating hospital. All hospi-
tals decided to participate. These additional data were
retrieved retrospectively from patient records, and com-
pleted protocols were returned to the study investigators.
Thrombolysis. The start of thrombolysis immediately
followed angiography, and control angiography was usually
performed once or twice daily or when there were signs of
clinical deterioration. Thrombolysis was administrated lo-
cally in the SMA with alteplase (Actilyse, Boehringer Ingel-
heim, Stockholm, Sweden) in all but one patient, who
received urokinase.
Follow-up. All patients were monitored from the day
of thrombolysis until death or March 30, 2011. Median
follow-up time was 15 months (interquartile range [IQR],
1-42; range, 0-123). All survivors had a minimum follow-up
of 1 year. Mortality data were retrieved from the Swedish
Population Registry.
Definitions. Glomerular filtration rate (GFR) was cal-
culated as a simplified variant of Modification of Diet in
Renal Disease Study Group.8 Renal insufficiency was pres-
ent if GFR was 60 mL/min in patients aged 50 to 65
years and50 mL/min in patients65 years. Anemia was
defined as hemoglobin 134 g/L in men and 117 g/L
in women. Ischemic heart disease included previous myo-
cardial infarction, angina pectoris, or previous coronary
intervention. Smoking included current and former to-
bacco smokers.
Absence or presence of peritonitis was determined by
clinical abdominal examination at admission. The distinc-
tion of embolus vs thrombosis was made by the appearance
and localization of the clot at CT and angiography and by
the presence of synchronous emboli. Atrial fibrillation and
a history of embolization were factors that suggested em-
bolism. Degree of lysis was stated as complete, partial, lysis
but no runoff, or no lysis.9 Complete and partial lysis refers
to complete dissolution with complete restoration of blood
flow and a minor to major reduction of thromboembolic
clot with improved blood flow, respectively. Technically,
successful thrombolysis is defined as complete or partial
lysis at the final angiography.
Statistical methods. Data management and statistical
analysis were performed using SPSS 18.0 software (SPSS
Inc, Chicago, Ill). Differences in proportions were evalu-
ated using the 2 test or the Fisher exact test. Continuous
variables were expressed as median and IQR or range, and
comparisons between two groups were made with the
Mann-Whitney U test. Long-term survival was analyzed
according to the Kaplan-Meier method. P  .05 was con-
sidered significant. iESULTS
Patient characteristics. The first patient received local
hrombolysis in 1997, and the annual incidence of throm-
olysis for acute SMA occlusion increased continuously in
weden between 2004 and 2009 (Fig 1). The 34 patients
ere a median age of 78 years (IQR, 69-86; range, 25-92),
ncluding five nonagenarians and 11 octogenarians.
wenty patients (59%) were women. Five patients (15%)
ad received local thrombolytic therapy previously in an-
ther arterial segment. The occlusion was embolic in 28
nd thrombotic in six, of whom one had an occlusion of a
tent in the SMA that had been placed to treat chronic
esenteric ischemia. Among patients with embolic disease,
4% had proven atrial fibrillation. The frequency of former
r current smokers was 46% (12 of 26). Table I reports the
requency of comorbidities and use of medications.
Symptoms and signs. One of the 34 patients (3%)
ad chronic mesenteric ischemia. The median time from
nset of abdominal pain to admission was 6 hours (IQR,
-21 hours) and from admission to attempting intestinal
evascularization was 9 hours (IQR, 4-30 hours). The
ode of onset of abdominal pain was sudden in 12 patients,
cute in 10, and insidious in 12. None of the patients had
cute peritonitis, and one (3%) had bloody stools at admis-
ion. The frequency of symptoms and signs are presented in
able I.
Laboratory data at admission. Themedian white cell
lood count was 12.4  109/L (IQR, 10.5-20.0  109/
), C-reactive protein (CRP) was 27 mg/L (IQR, 5-52
g/L), platelet concentration was 264 109/L, and GFR
as 63 mL/min/1.73 m2 (IQR, 44-80 mL/min/1.73
2). Renal insufficiency occurred in 36% and anemia in
8% of the patients (Table I). The prothrombin complex
alues among five patients receiving warfarin treatment
ere 1.2, 1.5, 1.5, 1.7, and 1.9 INR, respectively. D-dimer
as elevated in all 13 patients examined, and plasma lactate
as elevated in six of 16 (38%).
Diagnosis. The diagnosis was achieved with CT with
ntravenous contrast enhancement in 32 patients, ultra-
ound imaging in one, and angiography in one.
Synchronous emboli. Eleven patients (32%) had syn-
hronous emboli. The 24 identified additional arterial em-
oli were dislodged to the kidney in nine, spleen in five,
ower limb in five, upper limb in one, celiac trunk in two,
nd cerebrum in two. Four patients had bilateral renal
rtery emboli.
Angiographic findings in the SMA and thrombolysis.
hree Swedish centers performed five or more thrombo-
ytic treatments during the study period. The access was
chieved through the femoral artery in 30, brachial in three,
r both femoral and brachial arteries in one. Pharmacologic
hrombolysis was given with alteplase infusion in 33 pa-
ients and urokinase infusion in one. The median dose of
lteplase was 20 mg (IQR, 11.6-34.0 mg). A bolus dose
as given in 20 patients (59%). The median infusion rate
as 0.7 mg/h (IQR, 0.5-1.0 mg/h). Heparin was admin-
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December 20111736 Björnsson et al(74%). The median duration of thrombolysis was 22 hours
(IQR, 10.0-30.5 hours). Successful thrombolysis (com-
plete or partial effect) was achieved in 30 patients (88%;
Figs 2 and 3; Table II). Among the four patients with
failure of thrombolysis, the median dose of alteplase was
8.8 mg (range, 2.6-18.5 mg) and median duration was 8
hours (range, 2-17 hours).
Adjunctive endovascular procedures. Sixteen pa-
tients (47%) underwent an adjunctive endovascular proce-
dure at the time thrombolysis was initiated or during the
control angiographies: aspiration thromboembolectomy in
10, percutaneous transluminal angioplasty in three, me-
chanical thrombectomy in two with Rotarex (Straub
Medical, Wangs, Switzerland) and Angiojet (MEDRAD,
Warrendale, Pa), respectively, pulse spray thrombolysis
with alteplase in two, papaverine infusion in one, repeat
stenting after thrombolysis for an occluded stent in one,
and SMA stenting in one.
Laboratory data during thrombolysis. The maximal
activated partial thromboplastin time value was a median of
59 seconds (IQR, 46-85 seconds) in 26 patients during
thrombolysis, and the maximal CRP and plasma lactate
values were a median of 151 mg/L (IQR, 102-271 mg/L)
in 23 patients and 1.2 mmol/L (IQR 1.0-1.7 mmol/L) in
14. Two patients (14%) had a raised plasma lactate level
during thrombolysis.
Bleeding complications. Six bleeding complications
Fig 1. The annual number of patients treated with local
Sweden between 1997 and 2009.occurred in five patients, none of whom required a blood uransfusion, discontinuation of thrombolytic treatment, or
urgery. Three patients had local bleeding at the introducer
ite in the femoral (n  2) and the brachial (n  1) artery.
n explorative laparotomy in one patient found a hema-
oma centrally in the small bowel mesentery. One patient
ad self-limiting bleeding from the urinary and gastrointes-
inal tract.
Technical complications. Six technical complications
n four patients, three related to the access site and three to
he target artery, secondary to the endovascular proce-
ures, were noted. Thrombosis around the nonheparinized
ntroducer sheath at the access site occurred in two patients.
ne occlusion of the common femoral artery was managed
ith surgical thrombectomy, whereas the distal emboliza-
ion to the deep femoral and peroneal arteries was treated
onservatively. Inadvertent pullout of the percutaneous
emoral artery closure device (StarClose SE, Abbott Labo-
atories, Abbott Park, Ill) before clip deployment was man-
ged with the FemoStop compression assist device (St.
udeMedical, St. Paul, Minn). A guidewire perforation of a
mall bowel artery and a dissection of three SMA branches
fter aspiration embolectomy were managed conserva-
ively. A control angiography showed thrombolysis cathe-
er tip dislocation into the aorta during treatment and was
orrectly repositioned.
Explorative laparotomies, open intestinal revascular-
zations, and bowel resections. Thirteen patients (38%)
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Volume 54, Number 6 Björnsson et al 1737bolysis. Open embolectomy was performed in four patients
who all had a partial effect of thrombolysis (Fig 3), and
bowel resection in these patients was performed in three
and withheld in one after an attempt of bypass with syn-
thetic material from the iliac artery to SMA. One patient
underwent embolectomy first, then interposition graft with
vein material within the SMA, and bowel resection before
thrombolysis. Eight patients underwent bowel resection,
and the median length of these resections was 1.1 meters
(range, 0.4-3.0 meters).
Relaparotomies. Ten relaparotomies and two third-
look laparotomies were performed. Seven of 10 patients
who underwent relaparotomy underwent bowel resection,
whereas one of 24 patients who did not undergo relapa-
rotomy underwent explorative laparotomy and bowel re-
section (P .001). On-demand (unplanned) relaparotomy
was performed in seven patients, followed by open embo-
lectomy in four. Three patients underwent planned second-
look relaparotomy.
In-hospital mortality. In-hospital mortality was 26%
(9 of 34), and the 30-day mortality was 24% (8 of 34). The
median duration of hospital stay was 11 days (IQR, 7-20
days). The causes of death were intestinal ischemia in eight
and stroke secondary to cerebral emboli in one. Age was
not associated with death (P  .42), nor was the mode of
onset (sudden, acute, or insidious) abdominal pain (P 
Table I. Patient-related prognostic factors at admission
for in-hospital mortality in patients with acute superior






PNo. (%) No. (%)
All 34 9/34 (26)
Age 80 years 16 (47) 5/16 (31) .55
Women 20 (59) 6/20 (30) .58
Hypertension 22/32 (69) 7/22 (32) .19
Ischemic heart disease 17 (50) 7/17 (41) .052
Stroke/TIA 8/33 (24) 2/8 (25) .87
Previous vascular surgery 12 (35) 3/12 (25) .89
Diabetes mellitus 7 (21) 2/7 (29) .89
Medication
Platelet aggregation
inhibitor 23 (70) 7/23 (30) .54
Warfarin 5 (15) 2/5 (40) .46
Laboratory evaluation
Anemia 6 (18) 0/6 (0) .16
Renal insufficiency 12/33 (36) 4/12 (33) .36
Symptoms and signs
Vomiting 21 (62) 3/21 (14) .041
Diarrhea 12/33 (36) 3/12 (25) .82
Atrial fibrillation 21/33 (64) 8/21 (38) .065
Clinical triada 17 (50) 5/17 (29) .70
Embolus 28 (82) 8/28 (29) .55
Synchronous emboli 11 (32) 2/11 (18) .45
TIA, Transient ischemic attack.
aSevere abdominal pain withminimal abdominal signs, vomiting or diarrhea,
and source of embolus..37). None of the five patients with CRP 100 mg/L at hdmission died (P  .30). Five of seven patients who
nderwent on-demand relaparotomy died, whereas none
f the three patients who underwent planned second-look
elaparotomy died (P  .17).
Successful thrombolysis was associated with decreased
eath (P .048). Among the four failures of thrombolysis,
xplorative laparotomy without bowel resection was per-
ormed in one, and three patients died. The fourth patient
urvived despite lysis of the embolus, but no runoff at final
ngiography and a decision to withhold further surgical
reatment (Fig 3). The variables associated with death are
eported in Table I and Table II. The continuous variables
ssociated (P  .1) with death were shorter time from
dmission to attempting intestinal revascularization (P 
055), higher plasma lactate level at admission (P  .037),
igher creatinine level (P  .038), lower GFR (P  .018),
horter duration of thrombolysis (P  .044), and higher
lasma lactate level during thrombolysis (P  .044).
Long-term bowel morbidity and mortality. Among
he 25 patients who were discharged from the hospital,
hort-bowel syndrome occurred in one patient (4%) during
ollow-up. This patient depended on intravenous nutri-
ional support and died at 19 months of liver failure sec-
ndary to long-term parenteral nutrition. The crude 1-year
urvival rate was 59% (20 of 34). The long-term survival
urve and life-table are shown in Fig 4.
ISCUSSION
The observed number of thrombolytic treatments in-
reased, as expected, from 2004 to the end of the study.
his was probably a result of better diagnostic performance
f CT scanners during the last years and an increased
wareness reflecting a high scientific activity in some Swed-
sh hospitals. Local intra-arterial thrombolytic therapy for
cute SMA occlusion was feasible and effective, with a low
requency of laparotomy and bowel resection.1 The bleed-
ng complications were few, self-limiting, and without need
or blood transfusion, discontinuation of thrombolysis, or
urgical management. This minimally invasive percutane-
us endovascular treatment option seems to be quite at-
ractive for these often fragile and very old patients who
resent with an early stage of intestinal ischemia. However,
ost of the patients selected for the study had embolic
cclusion, none had acute peritonitis, and only one had
loody stools at admission. The results in the present study
nd opinions in current reviews10,11 were used to propose
n algorithm for the future management of patients with
cute SMA thromboembolism (Fig 5).
Acute embolic rather than thrombotic occlusion seems
o be more suitable for thrombolytic therapy.12 Because
mboli typically are dislodged to the periphery of the SMA
n an atherosclerosis-free segment, local pharmacologic
hrombolysis has the potential to dissolve the clot com-
letely with minimal trauma to the occluded artery. Saddle
mbolus lodged distally in the main stem (Fig 2) or frag-
ented emboli with occlusion of one or several side
ranches may be treated effectively by lysis from an end-
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December 20111738 Björnsson et almain clot to be able to exert lysis downstream tomore distal
embolic fragments. However, treatment of SMA thrombo-
sis with mechanical thrombectomy, followed by a long
period of adjunctive local thrombolysis for residual distal
embolizations, has been reported to be successful.3
Interestingly, the procedural time for endovascular re-
vascularization was the same as for open surgery to achieve
at least partial reperfusion of the bowels.3 In the present
Fig 2. A, Angiography shows the superior mesenteric a
SMA occlusion. B, Angiography after local intra-arteria
catheter just above the embolus shows reduction of
restoration of the circulation within the SMA. A check la
recovery was uneventful.study, aspiration of clot was used as an initial adjunctive mrocedure to thrombolysis in 29% of the patients with the
im to reduce the embolic mass in a more instant way to
chieve a more rapid reperfusion of viscera, which in turn
ay reduce the need of pharmacologic lysis of the residual
ass and small branch emboli. Both of these techniques
an be used effectively alone or when combined.4,12
Most of the study patients received heparin infusion
hrough the introducer sheath during thrombolytic treat-
(SMA) before the start of thrombolysis in a patient with
inistration of alteplase (20 mg) through an end-hole
mbolic mass. C, Completion angiography shows full
omy afterward showed normal-appearing intestines andrtery
l adm
the e
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Volume 54, Number 6 Björnsson et al 1739ducer site and none of them received heparin infusion
through the introducer sheath in conjunction with throm-
bolysis. One patient received intravenous heparin. This find-
ingmay indicate that heparin infusion through the introducer
Fig 3. Flowchart showsmanagement and survival in rela
(SMA).
Table II. Angiographic findings and procedure-related
prognostic factors for in-hospital death in patients with






PNo. (%) No. (%)
All patients 34 (100) 9 (26)
Angiographic findings
Total occlusion of SMA 25/33 (76) 8/25 (32) .066
Embolization to SMA
branches 8/33 (24) 1/8 (12) .64
Procedures
Effect of thrombolysis
Complete 14 2/14 (14)
Partial 16 4/16 (25)
Lysis but no runoff 1 0/1 (0)
No lysis 3 3/3 (100) .021
Adjunctive endovascular
procedure 16 (47) 3/16 (19) .34
Bleeding complication 5 (15) 1/5 (20) .72
Explorative laparotomy 13 (38) 5/13 (38) .21
Open revascularization after
lysis 4 3/4 (75) .048
Bowel resection 8 (24) 3/8 (38) .42
Repeat laparotomy 10 (29) 5/10 (50) .045
Center performing 5
thrombolysis 18 (53) 3/18 (17) .17sheath during thrombolysis should be recommended. iOnly one patient in the present study had a mild
pisode of transient gastrointestinal hemorrhage. In a study
omparing endovascular therapy, often with thrombolysis,
nd open surgery, one-third of the patients in both groups
ad bloody stools at admission, but the occurrence of
ostoperative gastrointestinal hemorrhage was very low,
ithout group differences.3 In a study of patients with
astrointestinal hemorrhage, a provocative protocol with in-
ravenous administration of urokinase andheparinwas used to
nduce bleeding for localization purposes, but sensitivity of
his rather controversial and somewhat hazardousmethodwas
ery low.13 Hence, the fear of fatal or life-threatening gastro-
ntestinal hemorrhage during thrombolysis seems to be un-
ounded and might be exaggerated. In the absence of acute
eritonitis, the risk of bleeding complications14-16 should
ot deter the clinician to go ahead with thrombolysis for
he treatment of this life-threatening condition. If needed,
arly explorative laparotomy can be performed after discon-
inuation of thrombolysis and reversal of heparin with
rotamine. In case of severe bleeding, there is no need of
eversal of alteplase after thrombolysis is stopped because it
as a short duration of effect and a negligible effect on
oagulation factors, whereas reversal of heparin is manda-
ory.16
A detailed analysis of the relaparotomies showed that
hese procedures mostly were performed on-demand due
o unsuccessful endovascular intestinal revascularization or
evelopment of bowel infarction, or both, and were asso-
iated with high mortality. Hence, few patients underwent
planned routine second-look relaparotomy. Even in a
ore unselected series of patients undergoing endovascular
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procedure to address bowel viability. Hence, it seems that
the introduction of emergency endovascular therapy for
acute SMA occlusion has altered the need for laparotomy
and bowel assessment. The information at completion con-
trol angiography, being an integrated part of endovascular
therapy, and active clinical follow-up during the first days
after intestinal revascularization seem to be good prognos-
tic indicators, and routine second-look laparotomy may
therefore no longer be considered mandatory. Neverthe-
less, in four patients with successful partial effect of lysis,
explorative laparotomy and an open SMA embolectomy
followed. It is impossible to tell if this clinical course was
due to reocclusion of the SMA or the presence of irrevers-
ible transmural bowel infarction already at the time throm-
bolysis was initiated. It might also have been considered
worthwhile to attempt embolectomy while performing
bowel resection in these patients.
The findings of a seemingly specific increase in plasma
lactate in acute mesenteric ischemia in the 1980s and
1990s,17,18 and the absence of a much better marker today,
has led to that many clinicians still use plasma lactate as a
diagnostic test. For instance, testing for plasma lactate was
performed in half of the present study population. Experi-
mental studies19,20 have shown that plasma lactatemerely is
Patients at risk     34(0.08)                 19 (0.09)               12 (0.09)      
Fig 4. Long-term survival of patients receiving local in
occlusion in Sweden. Numbers below time axis denote
cumulative proportion of patient survival at end of int
censored data.an unspecific marker of body tissue hypoperfusion and snaerobic metabolism, not reflecting the early phase of
njury to the ischemic intestinal mucosa. Instead, elevated
lasma lactate at admission and during thrombolysis was a
redictor for death in the present study. Several clinical
tudies have also found an association between high plasma
actate values and death.3,21,22 Plasma D-dimer, however,
as elevated in all measured cases, which confirms previous
ndings that D-dimer is a highly sensitive test for acute
ntestinal ischemia6,23 but lacks specificity.24,25
A limitation of the study is the small sample size,
educing the possibility of an appropriate multivariate anal-
sis. Furthermore, different techniques were used at the 12
ospitals during the long study period. Nevertheless, this is
o far the largest series of thrombolysis for acute SMA
cclusion that has been published.
ONCLUSIONS
Local thrombolysis for acute SMA occlusion is a mini-
ally invasive and effective treatment alternative in a se-
ected group of patients without peritonitis. Technique-
elated complications were few. Owing to the recent effect
f CT scanners on diagnosis and the development of endo-
ascular therapy in all vascular units, it is reasonable to
elieve that there will be a continuous increase in the
nnual number of local thrombolysis for acute SMA occlu-
 (0.09)                6 (0.09)                 4 (0.09) 
terial thrombolysis for acute superior mesenteric artery
ents at risk at respective time point. Standard error of
is shown within parentheses. The tick marks indicate         11
tra-ar
pati
ervalion in most developed countries.
Rk.
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Fig 5. Proposed algorithm for themanagement of patien
mesenteric artery (SMA) occlusion. #Palliative care shoul
intestinal infarction. *Bypass to the SMA with synthe
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